These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 8443238)

  • 21. Use of synthetic peptide analogues to localize lecithin:cholesterol acyltransferase activating domain in apolipoprotein A-I.
    Anantharamaiah GM; Venkatachalapathi YV; Brouillette CG; Segrest JP
    Arteriosclerosis; 1990; 10(1):95-105. PubMed ID: 2105091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alteration in apolipoprotein A-I 22-mer repeat order results in a decrease in lecithin:cholesterol acyltransferase reactivity.
    Sorci-Thomas MG; Curtiss L; Parks JS; Thomas MJ; Kearns MW
    J Biol Chem; 1997 Mar; 272(11):7278-84. PubMed ID: 9054424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LCAT activation properties of apo A-I CNBr fragments and conversion of discoidal complexes into spherical particles.
    Vanloo B; Taveirne J; Baert J; Lorent G; Lins L; Ruyschaert JM; Rosseneu M
    Biochim Biophys Acta; 1992 Oct; 1128(2-3):258-66. PubMed ID: 1420299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of lecithin cholesterol acyltransferase by a disulfide-linked apolipoprotein A-I dimer.
    Calabresi L; Franceschini G; Burkybile A; Jonas A
    Biochem Biophys Res Commun; 1997 Mar; 232(2):345-9. PubMed ID: 9125178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural and functional properties of the 154-171 wild-type and variant peptides of human lecithin-cholesterol acyltransferase.
    Peelman F; Goethals M; Vanloo B; Labeur C; Brasseur R; Vandekerckhove J; Rosseneu M
    Eur J Biochem; 1997 Nov; 249(3):708-15. PubMed ID: 9395317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deletion of N-terminal amino acids from human lecithin:cholesterol acyltransferase differentially affects enzyme activity toward alpha- and beta-substrate lipoproteins.
    Vickaryous NK; Teh EM; Stewart B; Dolphin PJ; Too CK; McLeod RS
    Biochim Biophys Acta; 2003 Mar; 1646(1-2):164-72. PubMed ID: 12637024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lecithin cholesterol acyltransferase (LCAT) activity in the presence of Apo-AI-derived peptides exposed to disorder-order conformational transitions.
    Aguilar-Espinosa SL; Mendoza-Espinosa P; Delgado-Coello B; Mas-Oliva J
    Biochem Biophys Res Commun; 2013 Nov; 441(2):469-75. PubMed ID: 24383078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction between apo A-I-containing lipoproteins and lecithin:cholesterol acyltransferase.
    Ikeda Y; Ohta T; Matsuda I
    Biochim Biophys Acta; 1994 Dec; 1215(3):307-13. PubMed ID: 7811716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of serum amyloid A on cholesterol esterification in human plasma.
    Steinmetz A; Hocke G; Saïle R; Puchois P; Fruchart JC
    Biochim Biophys Acta; 1989 Nov; 1006(2):173-8. PubMed ID: 2512983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An approach to the functional analysis of lecithin-cholesterol acyltransferase. Activation by recombinant normal and mutagenized apolipoprotein AI.
    Bruhn H; Stoffel W
    Biol Chem Hoppe Seyler; 1991 Mar; 372(3):225-34. PubMed ID: 1905134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural studies of a peptide activator of human lecithin-cholesterol acyltransferase.
    Buchko GW; Treleaven WD; Dunne SJ; Tracey AS; Cushley RJ
    J Biol Chem; 1996 Feb; 271(6):3039-45. PubMed ID: 8621698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of human lecithin-cholesterol acyltransferase in transgenic mice. Effect of human apolipoprotein AI and human apolipoprotein all on plasma lipoprotein cholesterol metabolism.
    Francone OL; Gong EL; Ng DS; Fielding CJ; Rubin EM
    J Clin Invest; 1995 Sep; 96(3):1440-8. PubMed ID: 7657816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apolipoprotein A-IGiessen (Pro143----Arg). A mutant that is defective in activating lecithin:cholesterol acyltransferase.
    Utermann G; Haas J; Steinmetz A; Paetzold R; Rall SC; Weisgraber KH; Mahley RW
    Eur J Biochem; 1984 Oct; 144(2):325-31. PubMed ID: 6489332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deletion of amino acids Glu146-->Arg160 in human apolipoprotein A-I (ApoA-ISeattle) alters lecithin:cholesterol acyltransferase activity and recruitment of cell phospholipid.
    Lindholm EM; Bielicki JK; Curtiss LK; Rubin EM; Forte TM
    Biochemistry; 1998 Apr; 37(14):4863-8. PubMed ID: 9538003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation.
    Hine D; Mackness B; Mackness M
    IUBMB Life; 2012 Feb; 64(2):157-61. PubMed ID: 22184096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A reconstituted high density lipoprotein containing the V156E mutant of apolipoprotein A-I exhibits anti-atherosclerotic activity in Apo-E deficient mice.
    Cho KH
    J Atheroscler Thromb; 2009 Jun; 16(3):217-29. PubMed ID: 19638715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel N-terminal mutation of human apolipoprotein A-I reduces self-association and impairs LCAT activation.
    Weers PM; Patel AB; Wan LC; Guigard E; Kay CM; Hafiane A; McPherson R; Marcel YL; Kiss RS
    J Lipid Res; 2011 Jan; 52(1):35-44. PubMed ID: 20884842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of end group blockage on the properties of a class A amphipathic helical peptide.
    Venkatachalapathi YV; Phillips MC; Epand RM; Epand RF; Tytler EM; Segrest JP; Anantharamaiah GM
    Proteins; 1993 Apr; 15(4):349-59. PubMed ID: 8460106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure and stability of apolipoprotein a-I in solution and in discoidal high-density lipoprotein probed by double charge ablation and deletion mutation.
    Gorshkova IN; Liu T; Kan HY; Chroni A; Zannis VI; Atkinson D
    Biochemistry; 2006 Jan; 45(4):1242-54. PubMed ID: 16430220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DYRK1A overexpression decreases plasma lecithin:cholesterol acyltransferase activity and apolipoprotein A-I levels.
    Tlili A; Noll C; Middendorp S; Duchon A; Jouan M; Benabou E; Hérault Y; Paul JL; Delabar JM; Janel N
    Mol Genet Metab; 2013 Nov; 110(3):371-7. PubMed ID: 23920041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.